



INTERIM REPORT

JANUARY–SEPTEMBER 2020

XVIVO PERFUSION AB (PUBL)

XVIVO Perfusion is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, enabling the treatment of organs, and maintaining organs in good condition outside of the body, pending transplantation. Currently, the company's product, Perfadex® Plus, has a market share of approximately 90 percent in the traditional cold preservation of lungs for transplantation. The company's products for warm perfusion, XPST™ and STEEN Solution™, have regulatory approval in all major markets, and were the first products that received regulatory approval from the FDA for warm perfusion of marginal lungs. XVIVO Perfusion also develops the next generation of pre-transplant heart storage products that aim to store and transport the heart from a donor in an optimized way, through non-ischemic heart preservation.

XVIVO Perfusion employs around 80 people at its headquarters in Gothenburg, Sweden, its offices in Lund, Sweden, Groningen, Netherlands, and its office for North & South America in Denver, CO, USA. The XVIVO share is listed on NASDAQ Stockholm and has the ticker symbol XVIVO.



FIRST IN THE WORLD WITH PRODUCTS FOR ALL MAJOR SOLID ORGANS

THIRD QUARTER 2020 (JUL - SEP)

Financial information

- Net sales of non-durable goods* in the quarter amounted to SEK 42.3 (50.1) million, corresponding to a decrease of 16 percent in SEK and 10 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 42.7 (54.3) million, corresponding to a decrease of 21 percent in SEK and 17 percent in local currency. The Covid-19 pandemic continued to have an impact on sales during the third quarter, but to a lower extent than in the second quarter. In the important markets the recovery, which began in the middle of the second quarter, has continued in the right direction as the pressure on intensive care has eased. Since transplantation is a life-sustaining treatment and transplants are prioritized by healthcare authorities worldwide, the company's assessment is that the long-term effect on demand for transplant products will remain unchanged.
- Sales from warm perfusion** represented 41 percent (41) of sales of non-durable goods.
- Operating income before depreciation and amortization (EBITDA) amounted to SEK -11.2 (9.0) million corresponding to an EBITDA margin of -26 percent (17). During the quarter EBITDA was affected by costs associated with organizational change of SEK 5.4 million, costs for a share-based bonus program for employees outside Sweden of SEK 12.5 million and acquisition costs of SEK 2.7 million. Adjusted for these costs of a total SEK 20.5 million, the company reported an EBITDA for the quarter of SEK 9.3 (6.8) million, corresponding to a positive EBITDA margin of 22 percent (13).
- Operating income amounted to SEK -18.7 (2.3) million, after depreciation and amortization of SEK 7.4 (6.7) million. Adjusted for the above-mentioned specific costs, operating profit amounted to SEK 1.8 million (0.0).
- Net income amounted to SEK -14.7 (4.9) million, resulting in earnings per share of SEK -0.51 SEK (0.19).
- Cash flow from operating activities during the quarter amounted to SEK -1.8 (15.6) million. Cash flow from investing activities amounted to SEK -14.6 (-18.0) million. Cash flow from financing activities amounted to SEK 486.1

million (-0.1) net and is primarily explained by a directed share issue of SEK 500 million less issuance costs of SEK 12.4 million and amortization of lease liabilities of SEK 1.5 million.

Significant events

- XVIVO entered into an agreement to acquire 100 percent of the shares in the Dutch medical technology company Organ Assist B.V. Organ Assist focuses mainly on developing machines and consumables for perfusion of liver and kidney. Through the acquisition, XVIVO becomes the first company in the world, within preservation and evaluation of organs, to actively conduct business in all major organ areas. The acquisition accelerates the company's strategy to become a global supplier of solutions and systems in all major organ areas. The purchase price amounted to a maximum of EUR 24 million, with an initial payment of EUR 20 million and a conditioned, additional purchase price of maximum EUR 4 million.
- The acquisition of Organ Assist was financed through a directed share issue. Investors included both existing and new shareholders, including Bure Equity AB, Swedbank Robur, Eccenovo AB (publ.), Fjärde AP-Fonden, Lannebo Fonder and Handelsbanken Fonder. The issue took place with no discount at a subscription price of SEK 236 and the company received approximately SEK 500 million. Issuance costs amounted to SEK 12.4 million.
- The first patient in the extended PrimECC® study was included.
- A reorganization, which affected the company's management team and all departments, has taken place with the aim of creating a more efficient and successful organization. The Management Team has been strengthened with a new Commercial Director, Johan Holmström and a new R&D Director Charlotte Walldal. Furthermore, the company's current CFO, Christoffer Rosenblad, has been appointed to a newly established position within XVIVO as Chief Operating Officer, COO, with effect from 1 December. The new CFO will be Kristoffer Nordström, XVIVO's current Finance Manager.
- The application period for warrant program series 2020/2022 expired on September 23 and a total of 374,000 warrants were subscribed for.

* See note 3 for the consolidated revenue segment ** STEEN Solution™ and products and services related to XPS™ and LS™.

MILESTONES PASSED DURING THE THIRD QUARTER

XVIVO acquires the Dutch medical technology company Organ Assist B.V

Directed share issue brings in SEK 500 million

The first patient is included in the extended PrimECC® study

Strategy plan until 2025 is adopted and a new organization is launched

THE PERIOD 2020 (JAN - SEP)

Financial information

- Net sales of non-durable goods* in the period amounted to SEK 114.5 (147.5) million, corresponding to a decrease of 22 percent in SEK and 22 percent in local currency. Total net sales (incl. durable goods) in the period amounted to SEK 119.6 (158.4) million, corresponding to a decrease of 25 percent in SEK and 24 percent in local currency. The Covid-19 pandemic has had a large impact on sales and product mix during the period.
- Sales from warm perfusion** represented 34 percent (43) of sales of non-durable goods.
- Operating profit before depreciation and amortization (EBITDA) amounted to SEK -9.1 million (20.3), corresponding to an EBITDA margin of -8 percent (13). Operating profit during the period was affected by costs associated with organizational change of SEK 9.9 million, cost reservation for the share-based bonus programs for employees outside Sweden of SEK 9.9 million and acquisition costs of SEK 2.7 million. Adjusted for these specific costs of a total of SEK 22.5 million, EBITDA for the period amounts to SEK 13.4 million (27.6), corresponding to an EBITDA margin of 11 percent (17).
- Operating income amounted to SEK -31.3 (2.3) million, after depreciation and amortization of SEK 22.2 (18.0) million. Adjusted for the above-mentioned specific costs, operating profit amounted to SEK -8.8 million (9.6).
- Net income amounted to SEK -24.2 (6.8) million, resulting in earnings per share of SEK -0.91 (0.26).
- Cash flow from operating activities for the period amounted to SEK 9.7 (36.7) million. Cash flow from investing activities amounted to SEK -44.3 (-57.5) million. Cash flow from financing activities amounted to SEK 484.5 million (26.2) net and is primarily explained by a directed share

issue of SEK 500 million less issuance costs of SEK 12.4 million, and amortization of lease liabilities of SEK 4.5 million.

Significant events

- Dag Andersson has been appointed new President and CEO. XVIVO Perfusion's founder and former CEO, Magnus Nilsson, remains as Senior Advisor to primarily work with R&D.
- Anne-Li Sigvardsson, MSc, has been appointed IP Manager (Chief Intellectual Property Officer). Andreas Wallinder, MD, PhD has been appointed Chief Medical Officer.
- During the period, the scientific journal Nature Communications published an article describing the company's heart preservation technology and showing the method is safe.
- The company's study for heart preservation prior to transplantation in Europe is complete to include the first patient.
- The further developed and more user-friendly Perfadex® Plus with Click Port has been launched worldwide.
- AKH University Hospital in Vienna, Austria, which is one of the three largest lung transplant clinics in Europe, has purchased an XPS™. An XPS™ has for the first time been delivered to a pediatric (children's) hospital in Rome, Italy. At the end of the period, 53 clinics had access to XPS, LS or LS™.

EVENTS AFTER THE PERIOD

- On October 1, 2020, XVIVO completed the acquisition of the total shares in the Dutch medical technology company Organ Assist B.V. The initial cash purchase price of approximately EUR 20 million has been paid and Organ Assist B.V. will be consolidated into XVIVO from October 1, 2020.
- On October 14, an Extraordinary General Meeting took place where Lars Henriksson and Lena Höglund were appointed as new members of the Board of Directors.

* See note 3 for the consolidated revenue segment ** STEEN Solution™ and products and services related to XPS™ and LS™.

CEO'S COMMENTS



During the third quarter of 2020, the acquisition of the Dutch med-tech company Organ Assist was the single most important event. During the quarter, the company also adopted a strategy plan for 2025 and launched a new organization. The five most important points in the strategy are to secure a high-

performing organization, develop XVIVO into a company with products for all organs, optimize commercial operations, drive customer-oriented innovation, and strengthen the company operationally. The new management team is now in place and has already begun the organizational change that will lead to XVIVO being the market leader in transplantation in 2025.

Through the acquisition of Organ Assist, XVIVO becomes the first company in the world to have products linked to transplantation within all major organ areas. The purchase price, which amounted to EUR 24 million, with an initial payment of EUR 20 million and conditional, additional purchase price of maximum EUR 4 million, was financed through a directed share issue of SEK 500 million to Swedish and international institutional investors. The issue was successful and was oversubscribed three times without a discount. Organ Assist will be included in the XVIVO accounts from October 1.

During the third quarter, sales showed a gradual recovery from the second quarter, which was strongly affected by Covid-19. Sales of non-durable goods during the quarter amounted to SEK 42 million. In local currency, this is a decrease of 10 percent compared with the same quarter last year. I am glad to note that sales from products in warm perfusion accounted for 41 percent of total sales of non-durable goods (same as during the third quarter of 2019). The cost reduction program that has been implemented has yielded

good results and EBITDA excluding costs for organizational change, warrant programs for employees outside Sweden and costs related to the acquisition of Organ Assist amounted to SEK 9 million. This corresponds to an EBITDA of 22 percent, which is a higher adjusted EBITDA than for the corresponding quarter in 2019, 13 percent.

Within the company's research portfolio, new, significant progress has been made, the most important of which is that the extended PrimeECC® study was initiated during the quarter. PrimeECC®, which is a CE-marked and patent-protected product, has been developed to reduce complications after heart surgery. The hope of XVIVO is that the study will show that the product gives fewer side effects than today's priming solutions. An earlier study from 2017, which included a total of 80 patients at Sahlgrenska University Hospital, showed that the product is safe and results in reduced side effects. The extended study that has now been initiated intends to expand and strengthen the clinical documentation for PrimeECC® and will include a total of 366 patients.

After a first full quarter as CEO, I can conclude that the organization possesses a high level of competence and has very committed employees. We have expanded the management team with a Commercial Director, a Research and Development Director, and a Chief Operating Officer. This will further strengthen the offer and the relationships with our customers. Our ambition is to continuously improve our liquids and machines and create conditions for taking our products to market faster and more efficiently.

I look forward with confidence to XVIVO continuing to lead the development of innovative solutions and machines to enable more patients to receive a high-quality organ transplant.

Dag Andersson
CEO

CONFERENCE CALL


CEO Dag Andersson will present the report in a conference call at 2.30 p.m. CET on Friday, October 23, 2020. Telephone UK: +44 203 608 5256 or USA: +1 404 458 0105. PIN: 905 912 591 #

THIRD QUARTER 2020 (JULY - SEPTEMBER)


Net Sales

The Covid-19 pandemic continued to have an impact on sales during the third quarter, but the recovery in compare with the second quarter was strong. The decline in lung transplants

NET SALES
ROLLING 12 MONTHS (SEK MILLIONS)*



NET SALES EXCL. DURABLE GOODS
ROLLING 12-MONTHS (SEK MILLIONS)



COMPILATION OF NET SALES AND EBITDA

SEK THOUSANDS	January - September		July - September		Whole year
	2020	2019	2020	2019	
Net Sales non-Durable Goods	114 498	147 456	42 309	50 137	206 857
Net Sales Durable Goods	5 086	10 965	427	4 197	13 980
Net Sales Total	119 584	158 421	42 736	54 334	220 837
Cost of Goods non-Durable Goods	-23 837	-33 668	-9 422	-11 677	-47 439
Cost of Goods Durable goods	-4 129	-7 646	-180	-4 114	-10 585
Cost of Goods Total	-27 966	-41 314	-9 602	-15 791	-58 024
Gross income non-Durable Goods	90 661	113 788	32 887	38 460	159 418
Gross margin non-Durable Goods, %	79%	77%	78%	77%	77%
Gross income Durable Goods	957	3 319	247	83	3 395
Gross income Total	91 618	117 107	33 134	38 543	162 813
Gross margin Total, %	77%	74%	78%	71%	74%
Selling expenses	-40 670	-42 414	-13 470	-14 376	-60 786
Administrative expenses	-19 179	-17 587	-8 462	-6 029	-24 739
Research and development costs	-40 292	-44 687	-11 233	-16 827	-62 651
Other operating revenues and expenses**	-22 825	-10 075	-18 631	966	-10 697
Operating Income	-31 347	2 344	-18 661	2 277	3 940
Deprecation of cost of goods sold	-642	-607	-211	-208	-815
Deprecation of administrative expenses	-2 400	-1 585	-880	-628	-2 216
Amortization of research and development expenses	-15 063	-11 931	-5 038	-4 697	-16 624
Deprecation of other operative expenses	-4 111	-3 854	-1 303	-1 215	-5 205
EBITDA	-9 131	20 321	-11 229	9 025	28 800
EBITDA, %	-8%	13%	-26%	17%	13%

EBITDA for the period July - September 2020 has been affected by costs amounting to SEK 20.5 million for the share-based incentive program for employees outside Sweden and costs for reorganization and acquisition. Adjusted for these costs, EBITDA for the period amounted to SEK 9.3 million (6.8), corresponding to an EBITDA margin of 22 (13) percent.

* See note 3 for the consolidated revenue segment ** See note 4 for "Other operating revenues and expenses"

Total sales of products for warm perfusion (STEEN Solution™, XPS™, LS™ and products and services related to the use of XPS™ and LS™) accounted for 42 percent (46) of total sales. Warm perfusion sales from non-durable goods (STEEN Solution™, products and services related to the use of the XPS™ and LS™) accounted for 41 percent (41) of the total sales of non-durable goods.

Income

The gross margin for non-durable goods during the quarter was 78 (77) percent. The total gross margin during the quarter was 78 (71) percent. The increase is primarily explained by changes in product mix.

Operating income before depreciation and amortization (EBITDA) amounted to SEK -11.2 (9.0) million, corresponding to an EBITDA margin of -26 percent (17). The operating income was affected by costs from organizational change of SEK 5.4 million, costs for a share-based bonus program for employees outside Sweden of SEK 12.5 million and acquisition costs of SEK 2.7 million. Adjusted for these costs of a total SEK 20.5 million, the company reported an EBITDA for the quarter of SEK 9.3 (6.8) million, corresponding to a positive EBITDA margin of 22 percent (13).

Operating income amounted to SEK -18.7 (2.3) million, after amortization and depreciation of SEK 7.4 (6.7) million. Adjusted for the above-mentioned specific costs, operating income amounted to SEK 1.8 million (0.0).

The company continues to deliver according to the previously communicated cost reduction program. Variable costs, such as consultancies and travel expenses, were reduced during the third quarter. Selling expenses in relation to sales for the quarter amounted to 32 percent (26) as fixed costs such as personnel costs were not reduced in relation to the reduced sales. The company has been able to maintain good activity in its marketing initiatives, whereby no furlough has been justified. R&D costs amounted to 26 percent (31) of sales. The decrease is explained with lower activity and more distinct priorities in the development projects. Government support has been received in the USA and Australia of SEK 1.8 million, which has been reported as reduced personnel costs, primarily in the sales and R&D function. Administrative expenses amounted to 20 percent (11) of sales. Adjusted for acquisition costs, administrative expenses amounted to 13 percent of sales.

Other operating revenues and expenses, net, during the quarter amounted to SEK -18.6 million (0.9). The item consists primarily of costs from organizational change, SEK -5.4 million and costs for a share-based incentive program for employees outside Sweden, SEK -12.5 million. The remaining part consists primarily of exchange rate translation effects. See note 4 for more information.

Financial income and expenses, net, for the quarter amounted to SEK -0.5 million (3.2). The decrease is because of a stronger Swedish krona and its impact on exchange rate conversions in cash and cash equivalents.

During the quarter, SEK 13.1 (15.6) million of the development costs were capitalized as an intangible asset. SEK 11.9 (14.7) million was attributable to investments in the Heart transplant project with aim of receiving regulatory approval in the USA, Europe and Australia. SEK 0.3 million (0.5) was attributable to PrimECC® and SEK 0.9 (0.4) million was attributable to product development in the rest of the product portfolio. Amortization of capitalized development costs for the quarter amounted to SEK 3.9 (3.9) million, of which SEK 3.9 (3.9) million was attributable to amortization of capitalized development costs for regulatory approvals for products within lung transplantation.

Cash flow

Cash flow from operating activities during the quarter amounted to SEK -1.8 (15.6) million, primarily due to the Covid-19 effect on sales. SEK 13.7 million (16.7) was invested in intangible assets and SEK 0.9 million (1.3) was invested in tangible assets. Cash flow from financing activities amounted to SEK 486.1 (-0.8) million net. The increase is primarily explained by funds raised through the directed share issue of SEK 500 million less issuance costs of SEK 12.4 million and amortization of lease liabilities of SEK 1.5 million. Exchange rate differences in cash and cash equivalents had a negative effect on cash flow for the quarter of SEK -1.2 million (2.6). Cash and cash equivalents at the end of the quarter amounted to SEK 608.4 million (197.6).

SIGNIFICANT EVENTS DURING THE QUARTER

XVIVO completes the acquisition of the Dutch medical technology company Organ Assist B.V

XVIVO entered into an agreement to acquire 100 percent of the shares in the Dutch medical technology company Organ Assist B.V. Organ Assist focuses mainly on developing machines and consumables for perfusion of liver and kidney. Through the acquisition, XVIVO becomes the first company in the world, within preservation and evaluation of organs, to actively conduct business in all major organ areas. The acquisition accelerates the company's strategy to become a global supplier of solutions and systems in all major organ areas. The purchase price amounted to a maximum of EUR 24 million, with an initial payment of EUR 20 million and a conditioned, additional purchase price of maximum EUR 4 million.

Directed share issue in connection with the acquisition raised SEK 500 million

The acquisition of Organ Assist was financed through a directed share issue which took place in the same day as the acquisition. Investors included both existing and new shareholders, including Bure Equity AB, Swedbank Robur, Eccenovo AB (publ.), Fjärde AP-Fonden, Lannebo Fonder and Handelsbanken Fonder. The

issue took place without discount at a subscription price of SEK 236 and the company raised approximately SEK 500 million. Issuance costs amounted to SEK 12.4 million. The number of shares and votes in XVIVO Perfusion AB (publ) was increased by 2,118,640 shares and amounts to 28,719,136.

First patient in the extended PrimECC® study included

PrimECC®, a CE-marked and patent-protected product, is developed to reduce complications after heart surgery. PrimECC® is a solution used to prime the heart-lung machine before open heart-surgery. Hundreds of thousands of heart surgeries are performed today each year worldwide using a heart-lung machine. The extended study that has now begun intends to expand and strengthen the clinical documentation for PrimECC® and will include a total of 366 patients.

Strengthened organization

A reorganization, which affected the company's management team and all departments, has taken place with the aim of creating a more efficient and successful organization. The management team has been strengthened with a new Commercial Director, Johan Holmström, and a new R&D Director, Charlotte Walldal. Furthermore, the company's current CFO, Christoffer Rosenblad has been appointed to a newly established position within XVIVO as Chief Operating Officer, COO. The new CFO will be Kristoffer Nordström, XVIVO's current Finance Manager. The changes will take effect on December 1, 2020. The cost of the reorganization is reported during the third quarter of 2020 and amounts to SEK 5.4 million.

Warrants program 2020/2022 finalized

The application period for warrants program series 2020/2022 expired on September 23, 2020 and a total of 374,000 warrants were subscribed for:

THE PERIOD 2020 (JANUARY - SEPTEMBER)

Net Sales

The Covid-19 pandemic has had a major impact on sales and product mix during the period. For March, April and May, the decline was heavy. After the summer months, which normally involve somewhat lower activity, some recovery has taken place in the more important markets.

Total net sales in the period amounted to SEK 119.6 (158.4) million, corresponding to a decrease of 25 percent in SEK and 24 percent in local currency. Net sales of non-durable goods* in the period amounted to SEK 114.5 (147.5) million, corresponding to a decrease of 22 percent in SEK and 22 percent in local currency.

Total sales from products for warm perfusion (STEEN Solution™, XPS™, LS™, and products and services related to the use of

the XPS™ and LS™) accounted for 37 (47) percent of the total sales. Warm perfusion sales from non-durable goods (STEEN Solution™, products and services related to the use of the XPS™ and LS™) accounted for 34 (43) percent of the total sales of non-durable goods. Sales of goods for warm perfusion were affected during the period because fewer EVLPs was being performed in general and partly due to delays in partner projects within warm perfusion.

Income

The gross margin for non-durable goods during the period was 79 (77) percent. The increase is mainly attributable to changes in product mix. The total gross margin during the period was 77 (74) percent. The increase is mainly attributable to changes in segment mix.

Operating income before depreciation and amortization (EBITDA) amounted to SEK -9.1 (20.3) million, corresponding to an EBITDA margin of -8 percent (13). Operating profit during the period was charged with costs associated with organizational change of SEK 9.9 million, cost reservation for the share-based bonus programs for employees outside Sweden of SEK 9.9 million and acquisition costs of SEK 2.7 million. Adjusted for these specific costs of a total of SEK 22.5 million, EBITDA for the period amounts to SEK 13.4 million (27.6), corresponding to an EBITDA margin of 11 percent (17).

Operating income amounted to SEK -31.3 (2.3) million, after depreciation of SEK 22.2 (18.0) million charged to the quarter. Adjusted for the above-mentioned specific costs, operating profit amounted to SEK -8.8 million (9.6).

As previously communicated, the company followed a cost reduction program during the second and third quarters. Variable costs, such as consulting and travel costs, were reduced during the period. In relation to sales, however, the company's total costs increased during the period when certain fixed costs such as personnel costs were not reduced in relation to the reduced sales. The company has been able to maintain good activity in development projects and marketing initiatives, whereby no furlough globally has been justified. Government support has been received in the USA and Australia of SEK 4.2 million, which has been reported as reduced personnel costs, primarily in the sales and R&D function. Selling expenses in relation to sales during the period was 34 percent (27). R&D costs expenses amounted to 34 percent (28) of sales. Administrative expenses amounted to 16 percent (11) of sales. Adjusted for acquisition costs, administrative expenses amounted to 14 percent of sales.

Net of other operating revenues and expenses during the period were SEK -22.8 (-10.1) million. The increase is mainly explained by costs associated with organizational change of SEK 9.9 million, cost reservation for the share-based bonus programs for employees outside Sweden of SEK 9.9 million and negative currency translation effects. See note 4 for more information.

* See note 3 for the consolidated revenue segment

During the period, SEK 41.6 (52.5) million of the development costs were capitalized as an intangible asset. SEK 36.7 (38.3) million was attributable to investments in the Heart transplant project with aim of receiving regulatory approval in the USA, Europe and Australia, SEK 2.8 (2.1) million was attributable to PrimECC® and SEK 2.1 (1.8) million was attributable to product development in the rest of the product portfolio. Amortization of capitalized development costs for the period amounted to SEK 11.6 (9.8) million, of which SEK 11.6 (9.8) million was amortization of capitalized development cost for regulatory approvals for the products in lung transplantation.

Cash flow

Cash flow from operating activities during the period amounted to SEK 9.7 (36.7) million, primarily due to the Covid-19 effect on sales. Cash flow from investment activities amounted to SEK 44.3 (57.5) million, whereof SEK 42.5 (54.4) million was invested in intangible assets and SEK 1.8 (3.1) million was invested in tangible assets. Cash flow from financing activities amounted to SEK 484 (26.2) million net. The increase is primarily explained by funds raised through the directed share issue of SEK 500 million, less issuance cost of SEK 12.4 million and amortization of lease liabilities of SEK 4.5 million. Exchange rate differences in cash and cash equivalents had a negative effect on cash flow for the period of SEK -1.4 million (5.1). Cash and cash equivalents at the end of the period amounted to SEK 608.4 (197.6) million.

Financing

XVIVO Perfusion's equity / assets ratio is strong and amounted to 93 percent (89) at the end of the period. The company's total credit facilities consist of an overdraft facility and it amounted to SEK 30 (30) million at the end of the period, of which SEK 0.0 million (0.0) was utilized.

SIGNIFICANT EVENTS DURING THE QUARTER

Organizational changes

Dag Andersson was appointed as the new President and CEO. XVIVO Perfusion's founder and former CEO, Magnus Nilsson, remains as Senior Advisor to primarily work with R&D. Dag Andersson started his new position on June 1, 2020. Dag has a background in healthcare as CEO of Diaverum AB from 2008 up until 2018 and before that worked for 15 years in leading positions at the medical technology company Mölnlycke Health Care.

Anne-Li Sigvardsson, MSc has been appointed Chief Intellectual Property Officer (CIPO). Anne-Li is responsible for the company's IP portfolio and has developed XVIVO Perfusions patent portfolio for PrimECC and Perfadex Plus, among other products. Andreas Wallinder, MD, PhD has been appointed Chief Medical Officer (CMO). Andreas is the indication leader for the company's heart preservation development and clinically responsible within the company.

Heart preservation study from Lund published in Nature Communications

During the period, the scientific journal Nature Communications published an article written by Professor Johan Nilsson, describing the use of XVIVO Perfusion's heart preservation technology developed by Professor Stig Steen. The results from the study show that our method is safe and functional for clinical use.

The company's trial for heart preservation in Europe is ready to include the first patient

The planned clinical trial for heart preservation prior to transplantation in Europe is ready to include the first patient. Due to the Covid-19 pandemic, clinics in Europe have temporarily paused clinical trials. The company has managed to maintain competence and resources during this period, which enables a powerful investment once the trial gets started.

Perfadex® Plus with Click Port launched globally during the first quarter

As XVIVO Perfusion has previously reported, the company has developed a new, 'ready to use' version for cold preservation of lungs, called Perfadex® Plus. The advantage of Perfadex® Plus is that it is ready to use and the clinic does not need to add buffer and calcium ions before use. The product is now available in all major markets globally. Patent applications for Perfadex® Plus have been filed in all major markets and in 2019 the European Patent Office approved the patent for Perfadex® Plus in Europe.

XPS™ sold to leading European lung transplant clinic and pediatric clinic

The AKH University Hospital in Vienna, Austria, which is one of the three largest lung transplant clinics in Europe, has purchased an XPS™. Furthermore, a pediatric transplant clinic in Rome, Italy has purchased an XPS™. This is the first XPS™ delivered to a children's hospital.

OUTLOOK FOR 2020 AND 2021

In 2020, XVIVO has been affected by the ongoing Covid-19 pandemic through the reduction in lung transplants. Available healthcare resources have largely focused on Covid-19 patients and thus the number of donated organs has decreased and waiting lists have increased. During March to May, the decline was sharp. In the important markets, the company has seen a gradual recovery, in the USA from May and in Europe from June. Both Australia and Canada have had a gradual recovery during the third quarter. The company currently estimates that the number of transplants, and thus the demand for XVIVO Perfusion products, will continue to increase. The extent of the impact on sales during the fourth quarter of 2020 and the first quarter of 2021 will depend on the extent to which the Covid-19 pandemic affects intensive care in the important markets. Transplantation is a life-sustaining treatment and transplants are prioritized by

health authorities around the world. For this reason, the company estimates that the long-term effect on demand for transplant products will remain unchanged.

The Covid-19 pandemic has also resulted in clinics around the world temporarily pausing all clinical research. The company will continue further development in lung transplantation, heart transplantation, and PrimECC® with the aim of starting clinical multicenter studies in Europe, the USA, and Australia as soon as the clinics allow clinical research. The study in heart transplantation in Europe is ready to start and the PrimECC® study in Sweden included the first patient during the third quarter. Expenses attributable to the development of heart transplantation and PrimECC® will be capitalized on an ongoing basis.

THE COMPANY IN BRIEF

Background

Organ transplantation is the last resort for patients with end-stage organ failure. There is an acute global shortage of donated organs which results in deaths among patients on the waitlist. At the same time many donated organs are deemed unsuitable for transplantation and go unutilized.

Operations

XVIVO Perfusion AB is a medical technology that addresses the global shortage of donated organs by developing, manufacturing and commercializing products for optimal storage during transportation, assessment and treatment of organs outside of the body, ensuring the safe use of more organs and ultimately giving more patients the chance of a life-saving transplant. Currently, the company's product, Perfadex® Plus, has a market share of approximately 90 percent in the traditional preservation of lungs for transplantation. The company's products for warm perfusion, XPS™ and STEEN Solution™, have regulatory approval in all major markets in the world, and were the first products to receive regulatory approval from the FDA for warm perfusion of marginal lungs.

Lung transplantation

A great problem in transplantation healthcare is the lack of available lungs. Currently in the USA, only around 20 percent of the available donated lungs are transplanted, as it is considered far too risky to transplant the remaining majority. By using XVIVO's product STEEN Solution™, the organ is cleared of harmful substances from the donor, thus creating a better environment for the organ's cells. The technology thereby allows the organ to "recover" when possible. It also allows for functional testing to be performed on the organ outside the body. In clinical use in the US, Europe, Australia, and Canada, it has emerged that once STEEN Solution™ perfusion has been carried out, many of the organs that were initially "rejected" are assessed as being usable and have been successfully transplanted into patients with end-stage lung disease. Therefore, the

use of STEEN Solution™ has the potential to increase the total number of lung transplants.

Heart transplantation

Based on the world leading research of Professor Stig Steen and Igelösa, XVIVO Perfusion's heart transplantation competence center in Lund (Sweden) develops a machine and solutions for heart preservation. The products are developed to increase the availability of donated hearts so that more heart transplants can be performed, and more patients can be given a last chance of a longer life. Future focus is to perform clinical multicenter studies and use the documentation of these studies as a basis for applications for regulatory approvals for the products on all major markets.

Other indications

The company also invests in preclinical and clinical research in transplantation of liver and kidney and in perfusion of organs remaining in the body, for example, drug administration to isolated organs and priming solutions for heart-lung machines.

Business concept

XVIVO Perfusion's business concept is to increase the survival rate of patients in need of an organ transplant by providing effective products that increase the availability and survival potential of organs once transplanted.

Vision

The company's vision is that no one should have to die waiting for a new organ.

Objective

The company's objective is to establish the perfusion of organs with STEEN Solution™ and other advanced solutions as the standard treatment in organ transplantation so that more of these lifesaving treatments can be performed.

Strategy

XVIVO Perfusion's strategy is focused on increasing the number of organs available for transplantation. Through development of products for perfusion of organs and through clinical trials on all major markets in the world, XVIVO Perfusion shows that perfusion of organs gives more organs available for transplantation and thus gives a larger number of patients a life-saving treatment.

OTHER INFORMATION

Organization and personnel

At the end of quarter, the number of employees was 63, of whom 27 were women and 36 were men. Of these, 36 people were employed in Sweden and 27 outside Sweden. In addition, the company uses around 5 consultants.

Information on transactions with related parties

During the period, one transaction was conducted with a related party. Board member Folke Nilsson has invoiced the company SEK 25.000 for consulting services regarding product development.

Risk management

XVIVO Perfusion is constantly working to identify, evaluate, and manage risks in different systems and processes. Risk analyses are performed continually with regard to the company's normal business activities and also in connection with activities that are outside XVIVO Perfusion's regular quality system.

The market risks that are determined to have particular importance for the future development of XVIVO Perfusion are access to financial funds and medical resources at clinics around the world. Operational risks primarily comprise risks that limit or prevent XVIVO Perfusion from developing, manufacturing and selling quality, effective and safe products. Legal and regulatory risks may arise from changes in legislation and other regulations. Changes in legislation or political decisions may affect the company's ability to run or develop the business. Including financial risks are the currency risk for the business.

The most important strategic and operative risks affecting the company are described in the 2019 annual report, which is available on the company website www.xvivoperfusion.com.

Seasonal effects

XVIVO Perfusion's sales are marginally affected by seasonal effects. Mainly in new treatments such as EVLP or warm perfusion of the lungs there are slightly less activity during the summer months.

Nomination Committee for the 2021 Annual General Meeting

The following members have been appointed to XVIVO Perfusion's Nomination Committee for the 2021 Annual General Meeting:

Henrik Blomquist, appointed by Bure Equity AB
Martin Lewin, appointed by Eccenovo AB
Caroline Sjösten, appointed by Swedbank Robur Fonder AB
Gösta Johannesson, Chairman of the Board

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company Nomination Committee which were determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on April 27, 2018. The members of the Nomination Committee together represent 30 percent of the votes attached to all voting shares in the company as of August 31, 2020.

Annual General Meeting

The Annual General Meeting of XVIVO Perfusion AB (publ) will be held on April 22, 2021 in Gothenburg. Shareholders who wish to have an item considered at the Annual General Meeting can submit a written request to the Board to this effect. Such a request for an item to be considered is to be sent to XVIVO Perfusion AB (publ), Att: Chairman of the Board, Box 53015, 400 14 Gothenburg, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Events after the end of the reporting period

On 1 October 2020, XVIVO completed the acquisition of the total shares in the Dutch medical technology company Organ Assist B.V. The completion of the acquisition was conditional upon XVIVO obtaining financing for the purchase price of a maximum EUR 24 million through a directed share issue that the company successfully carried out on 23 September. On October 1, XVIVO paid the initial cash purchase price of EUR 20 million and Organ Assist B.V. will be consolidated into XVIVO from 1 October 2020.

An Extraordinary General Meeting took place on October 14 as a consequence of the proposal from the Nomination Committee's to appoint Lars Henriksson and Lena Höglund as new members of the Board of Directors. The meeting voted in favor of the proposals. Dag Andersson resigned as a member of the board as a consequence of him being appointed as the CEO of the company in the second quarter.

The above events do not affect the assessment of the financial information in this report. No other significant events have occurred after the balance sheet date.

Gothenburg
October 23, 2020

The Board

This report has been reviewed by the company's auditors.

Review report

To the Board of Directors of XVIVO Perfusion AB (publ.)
Corp. id. 556561-0424

Introduction

We have reviewed the summary interim financial information (interim report) of XVIVO Perfusion AB (publ.) as of 30 September 2020 and the nine-month period then ended. The Board of Directors and the Managing Director are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements ISRE 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing practices and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared,

in all material respects, for the Group in accordance with IAS 34 and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act.

Göteborg 23 October 2020

KPMG AB

Daniel Haglund
Authorized Public Accountant

Financial reports

XVIVO Perfusion's interim reports are published on the company's website, www.xvivoperfusion.com. The following reports are planned to be submitted:

Report on Operations 2020: Thursday, January 28, 2021.
Interim Report January-March 2021: Wednesday,
April 21, 2021
Interim Report January-June 2021: Friday, July 9, 2021
Interim Report January-September 2021: Thursday
October 28, 2021
Report on Operations 2021: Thursday, January 27, 2022

For further information, please contact

Dag Andersson, CEO, +46 788 21 50,
dag.andersson@xvivoperfusion.com
Christoffer Rosenblad, CFO, +46 735 192159,
christoffer.rosenblad@xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on October 23, 2020 at 7.30 am.

This is a translation of the Swedish version of the report. When in doubt, the Swedish wording prevails.

CONDENSED CONSOLIDATED STATEMENT OF NET INCOME

SEKTHOUSANDS	January - September 2020	January - September 2019	July - September 2020	July - September 2019	Whole year 2019
Net sales	119 584	158 421	42 736	54 334	220 837
Cost of goods sold	-27 966	-41 314	-9 602	-15 791	-58 024
Gross income	91 618	117 107	33 134	38 543	162 813
Selling expenses	-40 670	-42 414	-13 470	-14 376	-60 786
Administrative expenses	-19 179	-17 587	-8 462	-6 029	-24 739
Research and development costs	-40 292	-44 687	-11 233	-16 827	-62 651
Other operating revenues and expenses*	-22 825	-10 075	-18 631	966	-10 697
Operating income	-31 347	2 344	-18 661	2 277	3 940
Financial income and expenses	22	5 188	-481	3 210	1 350
Income after financial items	-31 325	7 532	-19 142	5 487	5 290
Taxes	7 165	-691	4 457	-558	-351
Net income	-24 160	6 841	-14 685	4 929	4 939
Attributable to					
Parent Company's shareholders	-24 160	6 841	-14 685	4 929	4 939
Earnings per share, SEK	-0,91	0,26	-0,51	0,19	0,19
Earnings per share, SEK**	-0,89	0,26	-0,51	0,18	0,18
Average number of outstanding shares	26 639 730	26 491 229	28 601 434	26 600 496	26 518 546
Average number of outstanding shares**	27 013 730	26 826 496	28 975 434	26 879 496	26 799 996
Number of shares at closing day	28 719 136	26 600 496	28 719 136	26 600 496	26 600 496
Number of shares at closing day**	29 093 136	26 879 496	29 093 136	26 879 496	26 879 496
EBITDA	-9 131	20 321	-11 229	9 025	28 800
Amortization	-12 336	-10 432	-4 114	-4 099	-14 539
Depreciation	-9 880	-7 545	-3 318	-2 649	-10 321
Operating income	-31 347	2 344	-18 661	2 277	3 940

* See note 4 for "Other operating revenues and expenses"

** After dilution. See note 5 for information on warrant programs.

CONSOLIDATED STATEMENT OF TOTAL COMPREHENSIVE INCOME

SEKTHOUSANDS	January - September 2020	January - September 2019	July - September 2020	July - September 2019	Whole year 2019
Net income	-24 160	6 841	-14 685	4 929	4 939
Other comprehensive income					
<i>Items that may be reclassified to the income statement</i>					
Exchange rate differences	-3 231	7 412	-3 654	4 531	3 721
Tax attributable to items that have been transferred, or can be transferred to net income	153	-857	299	-487	-514
Total other comprehensive income, net after tax	-3 078	6 555	-3 355	4 044	3 207
Total comprehensive income	-27 238	13 396	-18 040	8 973	8 146
Attributable to					
Parent Company's shareholders	-27 238	13 396	-18 040	8 973	8 146

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

SEK THOUSANDS	Sep 30, 2020	Sep 30, 2019	Dec 31, 2019
ASSETS			
Goodwill	65 622	65 998	65 773
Capitalized development expenditure	296 526	252 819	266 517
Other intangible fixed assets	6 427	5 237	6 219
Fixed assets	21 780	23 014	23 554
Financial assets	19 880	12 594	12 539
Total non-current assets	410 235	359 662	374 602
Inventories	53 445	47 110	43 871
Current receivables	47 042	52 807	56 068
Liquid funds	608 374	197 643	159 946
Total current assets	708 861	297 560	259 885
Total assets	1 119 096	657 222	634 487
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholders' equity, attributable to the Parent Company's shareholders	1 041 891	582 623	577 521
Long-term interest-bearing leases	1 562	3 010	2 154
Long-term non-interest-bearing liabilities	2 719	3 551	2 213
Short-term interest-bearing leases	6 061	3 396	3 396
Short-term non-interest-bearing liabilities	66 863	64 642	49 203
Total shareholders' equity and liabilities	1 119 096	657 222	634 487

CONSOLIDATED KEY RATIOS

	January - September		July - September		Whole year
	2020	2019	2020	2019	2019
Gross margin non-Durable goods, %	79	77	78	77	77
Gross margin, %	77	74	78	71	74
EBITDA, %	-8	13	-26	17	13
Operating margin, %	-26	1	-44	4	2
Net margin, %	-20	4	-34	9	2
Equity/assets ratio, %	93	89	93	89	91
Income per share, SEK	-0,91	0,26	-0,51	0,19	0,19
Shareholders' equity per share, SEK	36,28	21,90	36,28	21,90	21,71
Share price on closing day, SEK	271,50	173,00	271,50	173,00	170,00

See page 18-19 for key ratios definition and reconciliation of alternative key figures.

CONDENSED CONSOLIDATED CASH FLOW STATEMENTS

SEKTHOUSANDS	January - September 2020		July - September 2019		Whole year 2019
Income after financial items	-31 325	7 531	-19 141	5 486	5 290
Adjustment for items not affecting cash flow	26 635	16 140	7 975	6 355	28 862
Paid taxes	-1 105	-2 763	-726	-1 202	-2 945
Change in inventories	-15 637	-10 370	-11 358	-1 515	-8 478
Change in trade receivables	12 533	5 750	-10 923	3 331	-542
Change in trade payables	18 632	20 435	32 291	3 122	7 318
Cash flow from operating activities	9 733	36 723	-1 882	15 577	29 505
Cash flow from investing activities	-44 343	-57 503	-14 597	-18 024	-83 844
Cash flow from financing activities	484 478	26 237	486 107	-758	25 551
Cash flow for the period	449 868	5 457	469 628	-3 205	-28 788
Liquid funds at beginning of period	159 946	187 064	139 993	198 215	187 064
Exchange rate difference in liquid funds	-1 440	5 122	-1 247	2 633	1 670
Liquid funds at end of period	608 374	197 643	608 374	197 643	159 946

CONSOLIDATED CHANGES IN SHAREHOLDERS EQUITY

SEKTHOUSANDS	Attributable to Parent Company's shareholders				Sum shareholders' equity
	Share capital	Other paid in capital	Reserves	Retained ear- nings incl. profit for the year	
Shareholders' equity as of 1 January, 2019	675	486 860	13 020	39 922	540 477
Total comprehensive income Jan - Sep, 2019			6 555	6 841	13 396
Issuing of new shares after deduction of incremental costs directly related to issuing new shares net of tax	5	27 321			27 326
Share warrant program		1 424			1 424
Shareholders' equity as of 30 September, 2019	680	515 605	19 575	46 763	582 623
Total comprehensive income October - December, 2019		148	-3 347	-1 903	-5 102
Shareholders' equity as of 31 december, 2019	680	515 753	16 228	44 860	577 521
Total comprehensive income January - Sep, 2020			-3 078	-24 160	-27 238
Issuing of new shares after deduction of incremental costs directly related to issuing new shares net of tax	54	490 223			490 277
Share warrant program		1 331			1 331
Shareholders' equity as of 30 september, 2020	734	1 007 307	13 150	20 700	1 041 891

CONDENSED CONSOLIDATED STATEMENT OF NET INCOME PER QUARTER

SEKTHOUSANDS	Jul - Sep 2020	Apr - Jun 2020	Jan - Mar 2020	Oct - Dec 2019	Jul - Sep 2019	Apr - Jun 2019	Jan - Mar 2019	Oct - Dec 2018
Net sales	42 736	30 393	46 455	62 416	54 334	56 437	47 650	58 389
Cost of goods sold	-9 602	-7 291	-11 073	-16 710	-15 791	-14 789	-10 734	-16 615
Gross income	33 134	23 102	35 382	45 706	38 543	41 648	36 916	41 774
Selling expenses	-13 470	-12 360	-14 840	-18 372	-14 376	-15 957	-12 081	-14 166
Administrative expenses	-8 462	-5 069	-5 648	-7 152	-6 029	-6 148	-5 410	-7 808
Research and development costs	-11 233	-12 186	-16 873	-17 964	-16 827	-12 898	-14 962	-12 560
Other operating revenues and expenses*	-18 631	-6 196	2 002	-622	966	-4 716	-6 325	-1 126
Operating income	-18 661	-12 709	23	1 596	2 277	1 929	-1 862	6 114
Financial income and expenses	-481	-6 047	6 550	-3 838	3 210	527	1 451	1 208
Income after financial items	-19 142	-18 756	6 573	-2 242	5 487	2 456	-411	7 322
Taxes	4 457	2 738	-30	340	-558	-229	96	-2 437
Net income	-14 685	-16 018	6 543	-1 902	4 929	2 227	-315	4 885
Attributable to								
Parent Company's shareholders	-14 685	-16 018	6 543	-1 902	4 929	2 227	-315	4 885
Earnings per share, SEK	-0,51	-0,60	0,25	-0,07	0,19	0,08	-0,01	0,19
Earnings per share, SEK**	-0,51	-0,60	0,25	-0,07	0,18	0,08	-0,01	0,19
Average number of outstanding shares	28 601 434	26 600 496	26 600 496	26 600 496	26 600 496	26 532 296	26 402 496	26 402 496
Average number of outstanding shares**	28 975 434	26 600 496	26 600 496	26 879 496	26 879 496	26 879 496	26 720 496	26 402 496
Number of shares at closing day	28 719 136	26 600 496	26 600 496	26 600 496	26 600 496	26 600 496	26 402 496	26 402 496
Number of shares at closing day**	29 093 136	26 600 496	26 600 496	26 879 496	26 879 496	26 879 496	26 879 496	26 402 496
EBITDA	-11 229	-5 452	7 550	8 479	9 025	8 055	3 241	10 485
Amortization	-4 114	-4 107	-4 115	-4 107	-4 099	-3 618	-2 715	-2 725
Depreciation	-3 318	-3 150	-3 412	-2 776	-2 649	-2 508	-2 388	-1 646
Operating income	-18 661	-12 709	23	1 596	2 277	1 929	-1 862	6 114

* See note 4 for "Other operating revenues and expenses"

** After dilution. See note 5 for information on warrant programs.

CONSOLIDATED STATEMENT OF TOTAL COMPREHENSIVE INCOME PER QUARTER

SEKTHOUSANDS	Jul - Sep 2020	Apr - Jun 2020	Jan - Mar 2020	Oct - Dec 2019	Jul - Sep 2019	Apr - Jun 2019	Jan - Mar 2019	Oct - Dec 2018
Net income	-14 685	-16 018	6 543	-1 902	4 929	2 227	-315	4 885
Other comprehensive income								
<i>Items that may be reclassified to the income statement</i>								
Exchange rate differences	-3 654	-5 226	5 649	-3 691	4 531	30	2 851	1 126
Tax attributable to items that have been transferred, or can be transferred to net income	299	319	-465	343	-487	-20	-350	-164
Total other comprehensive income, net after tax	-3 355	-4 907	5 184	-3 348	4 044	10	2 501	962
Total comprehensive income	-18 040	-20 925	11 727	-5 250	8 973	2 237	2 186	5 847
Attributable to								
Parent Company's shareholders	-18 040	-20 925	11 727	-5 250	8 973	2 237	2 186	5 847

CONDENSED INCOME STATEMENT FOR THE PARENT COMPANY

SEKTHOUSANDS	January - September		July - September		Whole year
	2020	2019	2020	2019	2019
Net sales	96 478	121 871	37 931	39 617	169 608
Cost of goods sold	-25 031	-33 163	-11 274	-13 761	-50 677
Gross income	71 447	88 708	26 657	25 856	118 931
Selling expenses	-25 032	-26 587	-8 361	-8 114	-36 502
Administrative expenses	-17 955	-11 889	-7 485	-3 953	-18 485
Research and development costs	-50 325	-49 646	-15 514	-17 277	-65 937
Other operating revenues and expenses	-8 569	-3 161	-7 208	-2 343	-181
Operating income	-30 434	-2 575	-11 911	-5 831	-2 174
Financial income and expenses	-153	9 840	-1 747	5 639	4 774
Income after financial items	-30 587	7 265	-13 658	-192	2 600
Year end dispositions		-	-	-	-2 300
Taxes	6 197	-382	2 788	204	-299
Net income	-24 390	6 883	-10 870	12	1

The Parent Company has no items to report as other comprehensive income, therefore a statement of comprehensive income is not presented.

Depreciation and amortization has reduced income for the period by SEK 14 978 (12 832) thousand, of which SEK 5 063 thousand (4 942) for the quarter.

CONDENSED BALANCE SHEET FOR THE PARENT COMPANY

SEKTHOUSANDS	Sep 30, 2020	Sep 30, 2019	Dec 31, 2019
ASSETS			
Intangible fixed assets	233 786	190 794	206 205
Fixed assets	6 416	6 030	7 924
Financial assets	183 756	193 966	194 166
Total non-current assets	423 958	390 790	408 295
Inventories	22 846	16 593	15 070
Current receivables	30 596	35 762	34 352
Cash and bank	597 762	183 260	150 362
Total current assets	651 204	235 615	199 784
Total assets	1 075 162	626 405	608 079
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholders' equity	1 015 427	554 860	548 150
Untaxed reserves	4 200	10 150	4 200
Provisions	1 310	1 318	6 734
Short-term non-interest-bearing liabilities	54 225	60 077	48 995
Total shareholders' equity and liabilities	1 075 162	626 405	608 079

SUPPLEMENTARY NOTES

Disclosures in accordance with IAS 34. I 6A occur in the financial statements and the related notes, as well as elsewhere in parts of the interim report.

Note 1. Accounting principles

For the Group, the report is presented pursuant to the Swedish Annual Accounts Act and IAS 34, Interim Financial Reporting, and for the Parent Company pursuant to the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities.

Accounting principles applied for the Group and the parent company correspond, unless otherwise stated below, with the accounting policies used for the preparation of the latest annual report.

Note 2. Financial instruments

The Group's financial assets and liabilities valued at acquisition value amount to SEK 655 (250) million and SEK 67 (65) million respectively. Fair value of the Group's financial assets and liabilities is assessed to correspond to the book value.

Note 3. Financial data per segment, Group

SEK Thousands	January - September					
	Net sales of non-Durable goods		Durable goods		Total consolidated	
	2020	2019	2020	2019	2020	2019
Net sales	114 498	147 456	5 086	10 965	119 584	158 421
Cost of goods sold	-23 837	-33 668	-4 129	-7 646	-27 966	-41 314
Gross income	90 661	113 788	957	3 319	91 618	117 107

SEK Thousands	July - September					
	Net sales of non-Durable goods		Durable goods		Total consolidated	
	2020	2019	2020	2019	2020	2019
Net sales	42 309	50 137	427	4 197	42 736	54 334
Cost of goods sold	-9 422	-11 677	-180	-4 114	-9 602	-15 791
Gross income	32 887	38 460	247	83	33 134	38 543

Note 4. Other operating revenues and expenses

TSEK	Jul - Sep 2020	Apr - Jun 2020	Jan-Mar 2020	Oct - Dec 2019	Jul - Sep 2019	Apr - Jun 2019	Jan-Mar 2019	Oct - Dec 2018
Cost of cash-based incentive program for employees outside Sweden	-12 469	-	2 541	237	2 253	-4 000	-5 536	812
Cost of reorganization	-5 375	-4 498	-	-	-	-	-	-
Other	-786	-1 698	-539	-859	-1 287	-716	-789	-1 938
Total	-18 630	-6 196	2 002	-622	966	-4 716	-6 325	-1 126

Note 5. Share warrant programs

In total there are 725.000 outstanding warrants in two programs.

The Annual General Meeting of 2019 resolved to issue no more than 351.000 warrants (series 2019/2021), with the right to subscribe a maximum of 351.000 new shares to employees of the XVIVO Perfusion Group. Of these warrants, all 351.000 have been subscribed by employees. Warrant program series 2019/2021 gives the warrant holder the right to subscribe for a new share in May 2021 at a price of SEK 278.91.

The Annual General Meeting of 2020 resolved to issue a maximum of 408.000 warrants (2020/2022 series) with the right to subscribe a maximum of 408.000 new shares to employees of the XVIVO Perfusion Group. Of these warrants, 374.000 have been subscribed for by employees. Warrant program 2020/2022 gives the warrant holder the right to subscribe for a new share in May 2022 at a price of SEK 205.88.

During the period July-september 2020, both the average share price for the period and the closing price at period end exceeded the exercise price of warrant program series 2020/2022, whereby the warrant program at strike is expected to result in a total dilution effect for existing shares of approximately 1.3 percent.

The Annual General Meeting in 2019 and 2020 decided to approve a cash-based incentive program for the Group's employees in countries outside Sweden, as these employees are not entitled to participate in the Swedish option programs. The cash-based programs should, as far as practically possible, be designed to correspond to the Swedish option programs but have a limit for maximum outcome. The cost of these cash-based incentive programs is recognized in the periods when XVIVO's share price exceeds the exercise price for each Swedish option program. The cost is reported under the item "Other operating income and expenses" and is described in Note 4.

Note 6. Acquisition of business

On October 1, XVIVO acquired 100 percent of the shares in the Dutch medical technology company Organ Assist B.V. The acquisition takes place at a cash purchase price of up to EUR 24 million, with an initial payment of EUR 20 million and potential additional purchase prices of a total of up to EUR 4 million. The additional purchase price is divided into two milestone payments, of a maximum of EUR 2 million each, based on sales targets for 2021 and regulatory approval in the USA for Organ Assist's kidney device. Costs attributable to the acquisition amounted to SEK 2.7 million and were charged to Administrative expenses in the consolidated income statement during the year. Organ Assist focuses mainly on developing machines and consumables for perfusion of the liver and kidneys. Through the acquisition, XVIVO will be the first company for the preservation and evaluation of organs in the world to actively conduct activities that include all major organs, which accelerates the company's strategy to become a global supplier of solutions and systems for all major organs. The companies' synergies enable greater market opportunities for XVIVO's and Organ Assist's product portfolios by integrating XVIVO's unique and patented STEEN Solution™ technology with Organ Assist's kidney and liver devices. And also by utilizing XVIVO's international market presence. The combined offering expands XVIVO's addressable market to approximately 98 percent of the organ transplant market with the goal of positioning the company as the first choice for all multi-organ clinics. The acquisition date is October 1 and income and cash flow are not included in the consolidated financial statements until this date. The acquired company's accounts have thus not contributed to the company's revenues and EBITDA during the third quarter. The table below shows the preliminary acquisition analysis.

Purchase price	Fair Value (TSEK)
Paid purchase price as at October 1, 2020	202 872
Conditional additional purchase price	40 781
Total	243 653
Intangible assets*	*
Tangible fixed assets	1 475
Inventories	14 360
Accounts receivable and other receivables	18 155
Liquid funds	1
Accounts payable and other liabilities	-31 257
Fair value of acquired net assets	2 734
Goodwill*	240 919
Total	243 653
Impact on the Group's cash flow	
Purchase price, initial payment in cash	202 872
Less: Cash and cash equivalents in acquired company	1
Impact on the Group's cash and cash equivalents	202 871

* Work is in progress to complete a full valuation of the identified, acquired intangible assets. Thus, this initial purchase price allocation will be adjusted when the fair values of acquired intangible assets are determined. This valuation is expected to be completed during the last quarter of 2020.

RECONCILIATION OF KPI NUMBERS

This report includes certain key ratios not defined in IFRS, but they are included in the report as company management considers that this information makes it easier for investors to analyze the Group's financial performance and position. Investors should regard these alternative key ratios as complementing rather than replacing financial information in accordance with IFRS.

EBITDA

SEK THOUSANDS	Jan - Sep 2020		Apr - Sep 2020		Whole year 2019
Operating income	-31 347	2 344	-18 661	2 277	3 940
Amortization	12 336	10 432	4 114	4 099	14 539
Depreciation	9 880	7 545	3 318	2 649	10 321
EBITDA	-9 131	20 321	-11 229	9 025	28 800

Gross margin

SEK THOUSANDS	Jan - Sep 2020		Apr - Sep 2020		Whole year 2019
<i>Operating income</i>					
Net sales	119 584	158 421	42 736	54 334	220 837
<i>Operating expenses</i>					
Cost of goods sold	-27 966	-41 314	-9 602	-15 791	-58 024
Gross income	91 618	117 107	33 134	38 543	162 813
Gross margin %	77	74	78	71	74

Gross margin non-Durable goods

SEK THOUSANDS	Jan - Sep 2020		Apr - Sep 2020		Whole year 2019
<i>Operating income</i>					
Net sales of non-Durable goods	114 498	147 456	42 309	50 137	206 857
<i>Operating expenses</i>					
Cost of non-Durable goods sold	-23 837	-33 668	-9 422	-11 677	-47 439
Gross income, non-Durable goods	90 661	113 788	32 887	38 460	159 418
Gross margin, non-Durable goods %	79	77	78	77	77

To calculate the gross profit margin, gross profit is first calculated by subtracting the cost of goods for resale from net sales. Gross profit is then divided by net sales to obtain the performance measure of "gross profit margin." Gross profit margin states the percentage of net sales that are converted into profit after cost of goods sold, and is impacted by such factors as pricing, the cost of raw materials and manufacturing, inventory impairment and trends in exchange rates.

Equity/assets ratio

SEK THOUSANDS	Sep 30, 2020	Sep 30, 2019	Dec 31, 2019
Shareholders' equity	1 041 891	582 623	577 521
Total assets	1 119 096	657 222	634 487

Equity/assets ratio %	93	89	91
------------------------------	-----------	-----------	-----------

Equity consists of share capital, other contributed capital, reserves and retained earnings, including the Group's profit for the year and non-controlling interests. Equity/assets ratio is calculated by dividing equity by total assets and is thus a measure of the percentage of assets that are financed by equity.

KPI DEFINITIONS

KEY RATIO	DEFINITION	JUSTIFICATION TO USE OF KEY RATIO
Gross margin non-Durable goods, %	Gross income segment non-Durable goods as a percentage of the net sales of segment non-Durable goods.	The company believes that the key ratio provides an in-depth understanding of the company's profitability for operations for non-Durable goods. Since the pricing strategy for durable goods differs from the pricing strategy from all other operations, the gross margin is excluded separately from durable goods.
Gross margin, %	Gross income as a percentage of the net sales for the period.	The company believes that the key ratio provides an in-depth understanding of the company's profitability.
EBITDA margin, %	Operating income before depreciation and amortization as a percentage of net sales for the period.	The company believes that the key ratio provides an in-depth understanding of the company's profitability.
Operating margin, %	Operating income as a percentage of net sales for the period.	The company believes that the key ratio provides an in-depth understanding of the company's profitability.
Net margin, %	Income for the period as a percentage of net sales for the period.	The company believes that the key ratio provides an in-depth understanding of the company's profitability.
Equity/assets ratio, %	Shareholders' equity and non-controlling interests as a percentage of total assets.	The company believes that the equity to asset ratio provides an in-depth understanding of the company's capital structure.
Shareholders' equity per share, SEK	Shareholders' equity in relation to the number of shares outstanding at closing day.	The key ratio has been included to give investors an overview of how the company's equity per share has evolved.
Earnings per share, SEK	Income for the period in relation to the average number of outstanding shares for the period.	The key ratio has been included to give investors an overview of how the company's earnings per share has evolved.
Earnings per share after dilution, SEK	Income for the period in relation to the average number of outstanding shares after dilution for the period.	The key ratio has been included to give investors an overview of how the company's equity per share after dilution has evolved.

GLOSSARY

The following explanations are intended to help the reader understand certain specific terms and expressions in XVIVO Perfusion's reports:

Preclinical study

Research performed before a drug or method of treatment is sufficiently documented to be studied in humans, for example the testing of substances in tissue samples and subsequent testing in experimental animals.

Clinical study/trial

An investigation in healthy or sick people to study the effect of a drug or method of treatment.

Medical device

Comprises devices used to diagnose a disease or treat a disease and as rehabilitation.

Obstructive lung disease

Disease where there is airway obstruction.

Perfusion

Passage of a fluid through an organ's blood vessels.

Evaluation

Evaluation of the function of an organ.

Preservation

Storage and maintenance of an organ outside the body before transplantation.

Ex vivo (Latin for "outside a living organism")

Biological processes in living cells and tissues when they are in an artificial environment outside the body: "Opposite" of in vivo.

In vivo

Biological processes in living cells and tissues when they are in their natural place in intact organisms.

EVLP or Ex Vivo Lung Perfusion

Perfusion of a lung outside the body. The procedure is normally done to evaluate a lung before transplantation.

Hypo-thermic non-ischemic perfusion of a heart

Circulation of a cold, donated heart with addition of oxygen and necessary nutrition's during transport to the recipient.

FDA or US Food and Drug Administration

The FDA is the USA's food and drug authority with responsibility for food, dietary supplements, drugs, cosmetics, medical equipment, radiology equipment, and blood products. FDA approval is required to market a medical device on the American market.

PMA or Premarket Approval

Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and efficacy of Class III medical devices. Class

III devices support or sustain human life, are of substantial importance in preventing impairment of human health, or potentially present an unreasonable risk of illness or injury.

HDE or Humanitarian Device Exemption

A humanitarian device exemption (HDE) application can be submitted to the FDA for a device that is intended to benefit patients by treating or diagnosing a disease or condition that affects or is manifested in fewer than 8,000 individuals in the United States per year. An HDE is similar in both form and content to a Premarket Approval (PMA) application, but is exempt from the efficacy requirements of a PMA.





OPO or Organ Procurement Organization

In the United States, an organ procurement organization (OPO) is a non-profit organization that is responsible for the evaluation and procurement of deceased-donor organs for organ transplantation. There are approximately 58 such organizations in the United States.

Reimbursement

Reimbursement is relevant within the health insurance system for healthcare providers to be paid faster and more easily for accrued expenses from a private or public insurance company (in the United States, e.g. Medicare).

CURRENT R&D PORTFOLIO

PROJECT	DESCRIPTION	STATUS
DEVELOPMENT PROJECTS		
Heart transplantation 	<p>What primarily limits how many people can receive a heart transplant today is the number of available, and using today's technology, usable donated organs, in combination with the time that a donated heart can be outside the body. XVIVO is working in collaboration with Professor Stig Steen to develop a holistic solution consisting of fluids and machinery that better preserve the function of the donated heart during transport and thus can contribute to improved results after heart transplantation.</p>	<p>The company is developing a program with clinical multicenter studies. These studies will form the basis for the application for regulatory approval of the products in all the major markets in the world. In Europe, a study is planned for 202 patients in eight centers in seven countries. Patients are selected by lottery to be transplanted either with donated hearts transported by XVIVO's method or preserved using the traditional icebox method. XVIVO expects to be able to start the study during the fourth quarter, though this will be dependent on the development of the Covid-19 pandemic. A similar multicenter study is in the planning phase in the US as well, where the company has received a so-called "breakthrough device designation" and the conditions for starting the study are under discussion with the FDA. During the third quarter, the first patients received transplanted hearts where XVIVO's technology was used within the framework of an ongoing Swedish investigator-driven study. A supplementary study of the products initiated by investigators is also being launched in Australia.</p>
PrimECC 	<p>PrimECC® is a fluid that has been developed in collaboration with Professor Stig Steen in Lund and is intended for use in a heart-lung machine. This machine completely assumes control of the function of the heart and lungs during the several hundred thousand heart operations that are performed annually. Before the heart-lung machine is connected to a patient, the machine must be filled with fluid, which today usually is a simple saline solution. The hope is that the use of PrimECC® for this purpose will reduce side effects related to the use of the heart-lung machine by protecting the body's organs.</p>	<p>XVIVO Perfusion has patents for PrimECC® in the important markets of the US, the EU, China, and Japan, and the product has already been granted a CE mark. In 2016 and 2017, a randomized clinical study of 80 patients was conducted which indicated positive effects of PrimECC. During the third quarter, Sahlgrenska University Hospital included the first patients in a new extended study that is planned to include 366 patients undergoing heart operation at one of the Swedish university hospitals. The company is waiting with the product launch until the study results have been analyzed.</p>
RESEARCH PROJECTS		
Liver transplantation 	<p>Similarly to other organs, there is a lack of transplantable livers. By preserving and evaluating the function of the donated liver in an optimized way, potentially more well-functioning organs could be transplanted. Studies indicate that perfusion of the liver before transplantation reduces the risk of complications.</p>	<p>The company's acquisition of Organ Assist brings technology, research, and development in warm perfusion of the liver in both preclinical and clinical, investigator-driven studies. Several of these clinical trials are in the final stages. The combination of new perfusion technology and XVIVO's solutions will be in focus for future research.</p>
Kidney transplantation 	<p>Similarly to other organs, there is a lack of transplantable kidneys. Studies have shown that transport of kidneys with ongoing perfusion in many cases improves post-transplant results. Evaluation of the kidney's function with warm perfusion is under development.</p>	<p>The company's acquisition of Organ Assist brings technology, research, and development in kidney perfusion in both preclinical and clinical, investigator-driven studies. The combination of new perfusion technology and XVIVO's solutions will be in focus for future research.</p>
Xeno-transplantation 	<p>Xenotransplantation is based on the use of non-human organs in transplantation. The method is currently in the research stage for several organs.</p>	<p>XVIVO's technology for preserving heart function is currently used by two world-leading research groups and has been crucial for successful results when genetically modified hearts from pigs are transplanted into primates. During the third quarter, important milestones were reached where trials with longer than 3 months survival were published.</p>

XVIVO PERFUSION'S PRODUCTS

WARM PERFUSION	WARM PERFUSION	WARM PERFUSION	COLD PERFUSION
 <p>XPS™, Durable goods</p>	 <p>XVIVO LS™, Durable goods</p>	 <p>STEEN Solution™</p>	 <p>PERFADEX® Plus</p>
 <p>XPS Disposable Lung Kit™</p>	 <p>XVIVO Disposable Lung Set™</p>	 <p>XVIVO Organ Chamber™</p>	 <p>XVIVO Silicone Tubing Set™</p>
		 <p>XVIVO Lung Cannula Set™</p>	



WWW.XVIVOPERFUSION.COM

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Tel: +46 31-788 21 50. Fax: +46 31-788 21 69.
XVIVO Perfusion Inc., 3666 South Inca Street, Englewood, CO 80110, USA, Tel: +1 303 395 9171, Fax +1 800 694 5897.
XVIVO Perfusion Lund AB, Propellervägen 16, SE-224 78 Lund, Sweden. Tel: +46 46 261 05 50. Fax: +46 31-788 21 69.
XVIVO Perfusion SAS, 3 Place Giovanni da Verrazzano, 69009 Lyon, France . Tel : +46 31-788 21 50. Fax: +46 31-788 21 69
XVIVO Perfusion Pacific Pty. Ltd., Level 18, 530 Collins Street, Melbourne, VIC 3000, Australia. Tel: +46 31-788 21 50. Fax: +46 31-788 21 69.
Organ Assist Products B.V., Bornholmstraat 84, 9723 AZ Groningen, The Netherlands. Tel: +31 50 313 1905.